Capricor Therapeutics Inc... (CAPR)
NASDAQ: CAPR
· Real-Time Price · USD
14.17
0.99 (7.51%)
At close: Jun 06, 2025, 1:58 PM
7.51% (1D)
| Bid | 14.15 |
| Market Cap | 647.68M |
| Revenue (ttm) | 17.36M |
| Net Income (ttm) | -55.06M |
| EPS (ttm) | -1.37 |
| PE Ratio (ttm) | -10.34 |
| Forward PE | -23.21 |
| Analyst | Buy |
| Ask | 14.17 |
| Volume | 1,515,872 |
| Avg. Volume (20D) | 2,067,055 |
| Open | 13.10 |
| Previous Close | 13.18 |
| Day's Range | 12.80 - 14.34 |
| 52-Week Range | 3.52 - 23.40 |
| Beta | 0.85 |
About CAPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CAPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CAPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-29.13%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
1 month ago
-13.15%
Capricor Therapeutics shares are trading lower. The company announced the completion of a mid-cycle review meeting with the FDA for the Company's Biologics License Application seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.
